ClinicalTrials.gg
CompletedNCT00327184Updated Oct 7, 2016

Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine

A Phase 3 interventional study of Haemophilus influenzae type b- and meningococcal serogroup C (vaccine) and Infanrix Penta in Neisseria Meningitidis and Haemophilus Influenzae Type b, sponsored by GlaxoSmithKline. Completed at 16 sites in 2 countries. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-07.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
709
Allocation
Randomized
Ages
6 Weeks to 12 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.

Enrollment
20th of 80
709 · median 445
Started
2006
with 13 others
Phase 3
48 of 82
none open now
Registered
28th of 82
by date

Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 20th largest by enrollment of the 80 interventional ones that give a count, is one of 14 that started in 2006, is one of 48 in phase 3, and was the 28th registered.

Haemophilus Infections

176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.

Browse Haemophilus Infections studies →

Open to participants now

None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →

Who these studies take

Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 82 studies in Haemophilus Infections by GlaxoSmithKline as a file.
02

Study summary

The purpose of this primary vaccination phase is to demonstrate the non-inferiority of two doses of Biologicals' Hib-MenC conjugate vaccine when given with Infanrix™ penta to infants (at 3 \& 5m) compared to NeisVac-C™ given with Infanrix™ hexa.

The purpose of the booster vaccination phase is to evaluate the immunogenicity, safety and reactogenicity of a booster dose of the Hib-MenC vaccine given with Infanrix™ penta at 11 m of age versus NeisVac-C™ given with Infanrix™ hexa, as well as the antibody persistence prior to the administration of the booster doses. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Read the detailed description

This multicenter study is open and consists of a primary and a booster phase. The study has 2 treatment groups with NeisVac-C™ + Infanrix™ hexa as active controls. In the primary phase, one blood sample will be collected from all subjects for immunogenicity analyses- one month after the second vaccination dose. In the booster phase, two blood samples will be collected: prior to and one month post booster vaccination.

03

Conditions studied

  • Neisseria Meningitidis
  • Haemophilus Influenzae Type b
04

Who can participate

Ages eligible
6 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Primary Phase:

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
  • healthy male or female subject between, and including, 6 and 12 weeks of age at the time of the first vaccination, born after a gestation period between and including 36 and 42 weeks.
  • Written obtained from the parent or guardian of the subject prior to the study entry.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Booster Phase:

  • Participation in primary phase of study.

Exclusion criteria

Exclusion Criteria

Primary Phase:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine(s) since birth or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of or other immune-modifying drugs since birth.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol since birth, with exception of BCG.
  • Previous vaccination against meningococcal serogroup C disease, diphtheria, tetanus, pertussis, polio, pneumococcal, or Hib disease
  • History of Haemophilus influenzae type b and /or meningococcal serogroup C disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Major congenital defects or serious chronic illness.
  • History of any neurologic disorders or seizures.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

Additional Exclusion criteria for the Booster Phase:

  • Previous booster vaccination with Hib and/or MenC and/or DTP containing and/or IPV containing and/or HepB containing vaccine(s).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
709 participants (actual)

Study arms

  • Experimental
    Group Hib-MenC

    Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of Hib-MenC + Infanrix™ penta vaccines.

    Biological: Haemophilus influenzae type b- and meningococcal serogroup C (vaccine) · Biological: Infanrix Penta

  • Active comparator
    Group NeisVac-C

    Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of NeisVac-C™ + Infanrix™ hexa vaccines.

    Biological: Infanrix hexa · Biological: Neis-Vac-C

Interventions

  • BiologicalHaemophilus influenzae type b- and meningococcal serogroup C (vaccine)

    Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.

  • BiologicalInfanrix Penta

    Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.

  • BiologicalInfanrix hexa

    Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age

  • BiologicalNeis-Vac-C

    Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age

06

What researchers measure

Primary outcomes

  1. SBA-MenC titre

    Time frame: One month after the second dose of the Primary Vaccination Phase.

  2. Anti-PRP concentration

    Time frame: One month after the second dose of the Primary Vaccination Phase

Secondary outcomes

  1. SBA-MenC titres

    Time frame: One month after the second dose of the Primary Vaccination Phase; prior to and one month after the Booster Vaccination

  2. Anti-PRP concentrations

    Time frame: One month after the second dose of the Primary Vaccination Phase; prior to and one month after the Booster Vaccination

  3. Anti-PSC concentrations

    Time frame: One month after the second dose of the Primary Vaccination Phase; prior to and one month after the Booster Vaccination.

  4. Anti-HBs concentrations

    Time frame: One month after the second dose of the Primary Vaccination Phase; prior to and one month after the Booster Vaccination

  5. Occurrence of local solicited adverse events.

    Time frame: During the solicited follow-up period (Day 0 - Day 3) following the administration of each vaccine dose.

  6. Occurrence of solicited general adverse events

    Time frame: During the solicited follow-up period (Day 0 - Day 3) following the administration of each vaccine dose.

  7. Occurrence of unsolicited non-serious adverse events

    Time frame: Within 30 days after each vaccination

  8. Occurrence of any serious adverse events

    Time frame: Throughout the study.

07

Study locations

16 sites
  • GSK Investigational Site
    Espoo, 02100, Finland
  • GSK Investigational Site
    Helsinki, 00100, Finland
  • GSK Investigational Site
    Helsinki, 00930, Finland
  • GSK Investigational Site
    Jarvenpaa, 04400, Finland
  • GSK Investigational Site
    Kotka, 48100, Finland
  • GSK Investigational Site
    Lahti, 15140, Finland
  • GSK Investigational Site
    Oulu, 90100, Finland
  • GSK Investigational Site
    Pori, 28120, Finland
  • GSK Investigational Site
    Tampere, 33200, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Vantaa, 01300, Finland
  • GSK Investigational Site
    Vantaa, 01600, Finland
  • GSK Investigational Site
    Lodi, Lombardia 26900, Italy
  • GSK Investigational Site
    Bari, Puglia 70124, Italy
  • GSK Investigational Site
    Sassari, Sardegna 07100, Italy
  • GSK Investigational Site
    Ragusa, Sicilia 97100, Italy
08

References and documents

Publications

  • Vesikari T, Forsten A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study. Pediatr Infect Dis J. 2013 May;32(5):521-9. doi: 10.1097/INF.0b013e31827e22e3. PubMed 23190785 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Nov 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2006
First posted
May 18, 2006
Start
Apr 2006
Primary completionActual
Nov 2006
CompletionActual
Nov 2006
Last update
Oct 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00327184
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 18, 2006
Start date
Apr 2006
Primary completion
Nov 2006
Completion
Nov 2006
Last update
Oct 7, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pediarix

Start the discussion